CRL
Charles River Laboratories International, Inc.
CRL has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over CRL overall, supported by stronger valuation and stronger fundamentals.
CRL Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Weak |
CRL's profitability is currently healthy, and its revenue and cash flow are stable, but its balance sheet is weak.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
CRL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 22x | $21.43 | -94% |
| Fair | 29x | $27.64 | -92% |
| Expensive | 46x | $44.08 | -87% |
| Current | 355x | $341 | — |
Historical ranges are pointers, not guarantees.
CRL's PE is in its expensive range at 355x.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over CRL in the historical PE scenario, which offers more potential upside but is not a forecast.
CRL Forward outlook
There aren't enough analyst estimates for CRL to show an outlook.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
CRL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.96 | +$2.47 |
| Q2 2026 | -$4.80 | -$3.52 |
| Q1 2026 | -$3.71 | -$3.11 |
| Q4 2025 | -$2.91 | -1555% |
| Q3 2025 | -$1.51 | -119% |
| Q2 2025 | -$1.28 | -115% |
| Q1 2025 | -$0.60 | -107% |
| Q4 2024 | $0.20 | -98% |
CRL has returned to profit: it earned $0.96 per share over the past year, after losing money the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over CRL on earnings, with more consistent year-over-year improvement.
CRL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $982.7M | -2.2% |
| Q2 2026 | $1B | -2.7% |
| Q1 2026 | $995.8M | +1.2% |
| Q4 2025 | $994.2M | -0.8% |
| Q3 2025 | $1B | -0.5% |
| Q2 2025 | $1B | +0.6% |
| Q1 2025 | $984.2M | -2.7% |
| Q4 2024 | $1B | -1.1% |
CRL's revenue grew through 2022 and has held roughly level since: $983M last quarter, down 2.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 21% | +7.3 points |
| Q2 2026 | 12% | +2.2 points |
| Q1 2026 | 12% | +4.4 points |
| Q4 2025 | -29% | -12 points |
| Q3 2025 | 13% | +1.7 points |
| Q2 2025 | 9.7% | -5.1 points |
| Q1 2025 | 7.6% | -4.9 points |
| Q4 2024 | -17% | -30 points |
CRL has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over CRL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
CRL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $207.3M | +16% |
| Q2 2026 | $148.6M | -12% |
| Q1 2026 | -$14.8M | -113% |
| Q4 2025 | $58.6M | -30% |
| Q3 2025 | $178.2M | -16% |
| Q2 2025 | $169.3M | +9.9% |
| Q1 2025 | $112.4M | +121% |
| Q4 2024 | $83.7M | -41% |
CRL still generates free cash flow, though less than at its 2024 peak: $400M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over CRL on cash flow, with more consistent year-over-year improvement.
CRL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +563K shares |
| 1 year | -1.7% | -842K shares |
| 3 years | -5.9% | -3M shares |
| 5 years | -5.8% | -3M shares |
| Available history | -2.2% | -1.1M shares |
CRL has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $224,000 |
| Q2 2026 | $115.6M |
| Q1 2026 | $208.3M |
| Q4 2025 | $96,000 |
| Q3 2025 | $93,000 |
| Q2 2025 | $7.4M |
| Q1 2025 | $353.1M |
| Q4 2024 | $124,000 |
CRL spent $324M buying back its own shares over the past year, down 10% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
CRL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 5.1x | High |
| Q2 2026 | 6.3x | High |
| Q1 2026 | 5.9x | High |
| Q4 2025 | 4.5x | High |
| Q3 2025 | 3.5x | Elevated |
| Q2 2025 | 3.9x | Elevated |
| Q1 2025 | 4.0x | Elevated |
| Q4 2024 | 3.5x | Elevated |
CRL's net debt is about 5.1 years of its operating earnings (EBITDA), up from 3.5 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over CRL on leverage, with a lower net debt burden relative to earnings.
CRL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 71.9 | Overbought |
| Stochastic | 75.1 | Neutral |
CRL's weekly RSI is 72 (overbought) and its Stochastic is 75 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
CRL PE vs Healthcare Sector
| Metric | CRL | Sector median | Relative |
|---|---|---|---|
| PE | 355x | 26x | 1,273% above |
| PE % | 96 | 29 | 67 pts above |
CRL is trading at 355x earnings, a 1273% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over CRL on valuation relative to its sector.
CRL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $321.0 | 6.2% above |
| 20 week MA | $284.7 | 20% above |
| 50 week MA | $223.9 | 52% above |
| 100 week MA | $191.1 | 78% above |
| 200 week MA | $201.5 | 69% above |
CRL has climbed back above all five of its weekly moving averages, and it's now 69% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
CRL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $151.9 | $251.7 | +66% |
| 2021 | $251.7 | $369.2 | +47% |
| 2022 | $369.2 | $218.5 | -41% |
| 2023 | $218.5 | $236.4 | +8.2% |
| 2024 | $236.4 | $186.2 | -21% |
| 2025 | $186.2 | $203.7 | +9.4% |
| 2026 YTD | $203.7 | $340.8 | +67% |
CRL has finished higher in four of the last six years. It's up 67% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over CRL on returns for 2026, with the stronger performance.